Geode Capital Management LLC Has $175,000 Holdings in GTx, Inc. (GTXI)

Geode Capital Management LLC trimmed its holdings in shares of GTx, Inc. (NASDAQ:GTXI) by 12.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 225,353 shares of the biopharmaceutical company’s stock after selling 31,391 shares during the period. Geode Capital Management LLC’s holdings in GTX were worth $175,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Virtu Financial LLC purchased a new stake in GTX during the fourth quarter valued at about $52,000. Vanguard Group Inc. boosted its position in GTX by 19.3% during the third quarter. Vanguard Group Inc. now owns 467,463 shares of the biopharmaceutical company’s stock valued at $734,000 after buying an additional 75,539 shares during the period. Vanguard Group Inc boosted its position in GTX by 19.3% during the third quarter. Vanguard Group Inc now owns 467,463 shares of the biopharmaceutical company’s stock valued at $734,000 after buying an additional 75,539 shares during the period. BlackRock Inc. boosted its position in GTX by 23.2% during the third quarter. BlackRock Inc. now owns 480,618 shares of the biopharmaceutical company’s stock valued at $755,000 after buying an additional 90,468 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in GTX during the fourth quarter valued at about $85,000. Institutional investors and hedge funds own 12.92% of the company’s stock.

NASDAQ GTXI opened at $1.06 on Friday. GTx, Inc. has a 12-month low of $0.74 and a 12-month high of $25.60.

ILLEGAL ACTIVITY WARNING: “Geode Capital Management LLC Has $175,000 Holdings in GTx, Inc. (GTXI)” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/17/geode-capital-management-llc-has-175000-holdings-in-gtx-inc-gtxi.html.

GTX Company Profile

GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.

Read More: Insider Trading

Want to see what other hedge funds are holding GTXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GTx, Inc. (NASDAQ:GTXI).

Institutional Ownership by Quarter for GTX (NASDAQ:GTXI)

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.